Paper19840887
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF and 10 others. Gynecol Oncol, 2010. Cited by 213 papers, by iCite.
Cite this record
ConductScience Library. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Papers, record 19840887. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19840887
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Agents | Major topic |
| Endometrial Neoplasms | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal, Humanized | |
| Female | |
| Gene Amplification | |
| Humans | |
| Immunohistochemistry | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Trastuzumab |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U10 CA027469 | NCI NIH HHS | United States | R10CA027469 | PubMed and NIH | NIH RePORTER |
| U10 CA037517 | NCI NIH HHS | United States | U10CA037517 | PubMed and NIH | NIH RePORTER |
| CA 37517 | NCI NIH HHS | United States | U10CA037517 | PubMed and NIH | NIH RePORTER |
| CA 27469 | NCI NIH HHS | United States | R10CA027469 | PubMed and NIH | NIH RePORTER |
| U10CA027469 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 20172595 | Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010). | https://conductscience.org/library/papers/20172595 |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8622019 | Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8622019 | PubMed |
| 2 | 16683005 | Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. | Nat Clin Pract Oncol | 2006 | https://conductscience.org/library/papers/16683005 | PubMed |
| 3 | 9280033 | Bayesian interim analysis of phase II cancer clinical trials. | Stat Med | 1997 | https://conductscience.org/library/papers/9280033 | PubMed |
| 4 | 16803532 | Use of trastuzumab in the treatment of metastatic endometrial cancer. | Int J Gynecol Cancer | 2006 | https://conductscience.org/library/papers/16803532 | PubMed |
| 5 | 9819829 | Optimal flexible designs in phase II clinical trials. | Stat Med | 1998 | https://conductscience.org/library/papers/9819829 | PubMed |
| 6 | 16322209 | High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. | Cancer Res | 2005 | https://conductscience.org/library/papers/16322209 | PubMed |
| 7 | 18316611 | Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. | Cancer Res | 2008 | https://conductscience.org/library/papers/18316611 | PubMed |
| 8 | 17945336 | An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. | Gynecol Oncol | 2008 | https://conductscience.org/library/papers/17945336 | PubMed |
| 9 | 17611206 | Trastuzumab--mechanism of action and use in clinical practice. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17611206 | PubMed |
| 10 | 18221484 | Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. | Int J Gynecol Cancer | 2008 | https://conductscience.org/library/papers/18221484 | PubMed |
| 11 | 16710036 | HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16710036 | PubMed |
| 12 | 18555254 | Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. | Int J Gynaecol Obstet | 2008 | https://conductscience.org/library/papers/18555254 | PubMed |
| 13 | 16166416 | Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16166416 | PubMed |
| 14 | 17908983 | Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17908983 | PubMed |
| 15 | 14752523 | Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. | Mod Pathol | 2004 | https://conductscience.org/library/papers/14752523 | PubMed |
| 16 | 17009989 | HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. | Int J Gynecol Cancer | 2006 | https://conductscience.org/library/papers/17009989 | PubMed |
| 17 | 16328593 | Antibody-based targeted therapy for gastric cancer. | Gastric Cancer | 2005 | https://conductscience.org/library/papers/16328593 | PubMed |
| 18 | 10561337 | Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561337 | PubMed |
| 19 | 18508484 | Her2 cross talk and therapeutic resistance in breast cancer. | Front Biosci | 2008 | https://conductscience.org/library/papers/18508484 | PubMed |
| 20 | 15894362 | Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. | Gynecol Oncol | 2005 | https://conductscience.org/library/papers/15894362 | PubMed |
Cited by102
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 213 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42630891 | Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42630891 | PubMed |
| 42449635 | Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449635 | PubMed |
| 41892160 | Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41892160 | PubMed |
| 41568388 | Human epidermal growth factor receptor 2 expression in gynecologic serous carcinomas and preliminary analysis of its characteristics in patients post-neoadjuvant chemotherapy. | Front Oncol | 2025 | https://conductscience.org/library/papers/41568388 | PubMed |
| 41496508 | ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression. | J Pathol | 2026 | https://conductscience.org/library/papers/41496508 | PubMed |
| 41306899 | Genomics of uterine malignancies and the potential of precision medicine. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/41306899 | PubMed |
| 41294658 | Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41294658 | PubMed |
| 41270342 | AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer. | Gynecol Oncol | 2026 | https://conductscience.org/library/papers/41270342 | PubMed |
| 41211166 | Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/41211166 | PubMed |
| 40862761 | HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma. | Cells | 2025 | https://conductscience.org/library/papers/40862761 | PubMed |
| 40195456 | HER2 testing: evolution and update for a companion diagnostic assay. | Nat Rev Clin Oncol | 2025 | https://conductscience.org/library/papers/40195456 | PubMed |
| 40056788 | Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma. | Int J Gynecol Cancer | 2025 | https://conductscience.org/library/papers/40056788 | PubMed |
| 39118940 | Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers. | Ann Transl Med | 2024 | https://conductscience.org/library/papers/39118940 | PubMed |
| 38658487 | High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options. | Reprod Sci | 2024 | https://conductscience.org/library/papers/38658487 | PubMed |
| 38262242 | A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). | Gynecol Oncol | 2024 | https://conductscience.org/library/papers/38262242 | PubMed |
| 38256137 | Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38256137 | PubMed |
| 37956617 | High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer. | Gynecol Oncol | 2023 | https://conductscience.org/library/papers/37956617 | PubMed |
| 37558129 | HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. | Mod Pathol | 2023 | https://conductscience.org/library/papers/37558129 | PubMed |
| 37368179 | New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. | Cancer Metastasis Rev | 2023 | https://conductscience.org/library/papers/37368179 | PubMed |
| 37345001 | HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345001 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MET | 4233 | PubTator's text mining | https://conductscience.org/library/genes/4233 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| PIK3R1 | 5295 | PubTator's text mining | https://conductscience.org/library/genes/5295 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
| UNK | 85451 | PubTator's text mining | https://conductscience.org/library/genes/85451 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19840887
GET https://conductscience.org/api/papers/v1/19840887/cited_by?page=2